Simultaneous polysubstance use among Danish 3,4- methylenedioxymethamphetamine and hallucinogen users: Combination patterns and proposed biological bases

Human Psychopharmacology

Volumn 27, Issue 4, 2012, Pages 352-363

  Licht, Cecilie L ^a,c   Christoffersen, Maria ^a   Okholm, Mads ^a   Damgaard, Lærke ^a   Fink Jensen, Anders ^b   Knudsen, Gitte M ^a   Erritzoe, David ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

3,4 methylenedioxymethamphetamine; designer drugs; ecstasy; hallucinogens; street drugs; substance related disorders

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMPHETAMINE; CANNABIS; COCAINE; LYSERGIDE; PSILOCYBINE; PSYCHEDELIC AGENT;

ADULT; ADVERTIZING; ARTICLE; CROSS-SECTIONAL STUDY; DENMARK; FEMALE; HAIR; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; STRUCTURED INTERVIEW; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DENMARK; FEMALE; HAIR; HALLUCINOGENS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84864132770     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2234     Document Type: Article

References (58)

1. Barrett SP, Archambault J, Engelberg MJ, Pihl RO,. 2000. Hallucinogenic drugs attenuate the subjective response to alcohol in humans. Hum Psychopharmacol 15: 559-565.
2. Barrett SP, Gross SR, Garand I, Pihl RO,. 2005. Patterns of simultaneous polysubstance use in Canadian rave attendees. Subst Use Misuse 40: 1525-37.
3. Barrett SP, Darredeau C, Pihl RO,. 2006. Patterns of simultaneous polysubstance use in drug using university students. Hum Psychopharmacol 21: 255-63.
4. Baumann MH, Wang X, Rothman RB,. 2007. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189: 407-24.
5. Boys A, Lenton S, Norcross K,. 1997. Polydrug use at raves by a Western Australian sample. Drug Alcohol Rev 16: 227-34.
6. Boys A, Marsden J, Strang J,. 2001. Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res 16: 457-69.
7. Breen C, Degenhardt L, Kinner S, et al,. 2006. Alcohol use and risk taking among regular ecstasy users. Subst Use Misuse 41: 1095-109.
8. Brown SA, Myers MG, Lippke L, Tapert SF, Stewart DG, Vik PW,. 1998. Psychometric evaluation of the Customary Drinking and Drug Use Record (CDDR): a measure of adolescent alcohol and drug involvement. J Stud Alcohol 59: 427-38.
9. Capela JP, Carmo H, Remiao F, Bastos ML, Meisel A, Carvalho F,. 2009. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 39: 210-71.
10. Carlson RG, Wang J, Falck RS, Siegal HA,. 2005. Drug use practices among MDMA/ecstasy users in Ohio: a latent class analysis. Drug Alcohol Depend 79: 167-79.
11. Clemens KJ, Cornish JL, Li KM, Hunt GE, McGregor IS,. 2005. MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats. Neuropharmacology 49: 195-207.
12. Clemens KJ, McGregor IS, Hunt GE, Cornish JL,. 2007. MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research. Drug Alcohol Rev 26: 9-15.
13. Diller AJ, Rocha A, Cardon AL, Valles R, Wellman PJ, Nation JR,. 2007. The effects of concurrent administration of +/-3,4-methylenedioxymethamphetamine and cocaine on conditioned place preference in the adult male rat. Pharmacol Biochem Behav 88: 165-70.
14. Dumont GJ, Kramers C, Sweep FC, et al,. 2009. Cannabis coadministration potentiates the effects of "ecstasy"on heart rate and temperature in humans. Clin Pharmacol Ther 86: 160-6.
15. Ekholm O, Kjoeller M, Davidsen M, et al,. 2006. Sundhed og sygelighed i Danmark & udviklingen siden 1987. [Health and morbidity in Denmark & the development since 1987]. Statens Institut for Folkesundhed, Copenhagen.
16. EMCDDA. 2009. Selected Issue, Polydrug Use: Patterns and Responses. European Monitoring Centre for Drugs and Drug Addiction, Lisbon.
17. EMCDDA. 2010. Annual Report 2010: The State of the Drugs Problem in Europe. European Monitoring Centre for Drugs and Drug Addiction, Lisbon.
18. Erritzoe D, Frokjaer VG, Holst KK, et al,. 2011. In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users. Arch Gen Psychiatry 68: 562-76.
19. Forsyth AJ,. 1996. Places and patterns of drug use in the Scottish dance scene. Addiction 91: 511-21.
20. Grov C, Kelly BC, Parsons JT,. 2009. Polydrug use among club-going young adults recruited through time-space sampling. Subst Use Misuse 44: 848-64.
21. Gudelsky GA, Yamamoto BK,. 2008. Actions of 3,4- methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 90: 198-207.
22. Halpern JH,. 2003. Hallucinogens: an update. Curr Psychiatry Rep 5: 347-54.
23. Hamida SB, Tracqui A, de Vasconcelos AP, et al,. 2009. Ethanol increases the distribution of MDMA to the rat brain: possible implications in the ethanol-induced potentiation of the psychostimulant effects of MDMA. Int J Neuropsychopharmacol 12: 749-59.
24. Hammersley R, Ditton J, Smith I, Short E,. 1999. Patterns of ecstasy use by drug users. Brit J Criminol 39: 625-647.
25. Hernandez-Lopez C, Farre M, Roset PN, et al,. 2002. 3,4- Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300: 236-44.
26. Johannsen M,. 2008. Ecstasy I Danmark 2007 [Ecstasy in Denmark 2007]. Aarhus Universitet, Retskemisk Afdeling.
27. Johansen SS, Jornil J,. 2009. Determination of amphetamine, metamphetamine, MDA and MDMA in human hair by GC-EI-MS after derivatization with perfluorooctanoyl chloride. Scan J Clin Lab Invest 69: 113-120.
28. Jones BC, Ben-Hamida S, de Vasconcelos AP, et al,. 2010. Effects of ethanol and ecstasy on conditioned place preference in the rat. J Psychopharmacol 24: 275-9.
29. Kish SJ, Lerch J, Furukawa Y, et al,. 2010. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[11C]DASB and structural brain imaging study. Brain 133: 1779-1797.
30. Martinez D, Narendran R, Foltin RW, et al,. 2007. Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 164: 622-9.
31. Mohamed WM, Ben Hamida S, Cassel JC, de Vasconcelos AP, Jones BC,. 2011. MDMA: interactions with other psychoactive drugs. Pharmacol Biochem Behav 99: 759-74.
32. Morley KC, Li KM, Hunt GE, Mallet PE, McGregor IS,. 2004. Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ("Ecstasy") in rats. Neuropharmacology 46: 954-65.
33. Nichols DE,. 2004. Hallucinogens. Pharmacol Ther 101: 131-81.
34. Panos JJ, Baker LE,. 2010. An in vivo microdialysis assessment of concurrent MDMA and cocaine administration in Sprague-Dawley rats. Psychopharmacology (Berl) 209: 95-102.
35. Parrott AC,. 2005. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 19: 71-83.
36. Parrott AC,. 2006. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J Psychopharmacol 20: 147-63.
37. Parrott AC,. 2009. Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users. Neuropsychobiology 60: 148-158.
38. Parrott AC, Milani RM, Parmar R, Turner JD,. 2001. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology (Berl) 159: 77-82.
39. Parrott AC, Milani RM, Gouzoulis-Mayfrank E, Daumann J,. 2007. Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users. J Neural Transm 114: 959-68.
40. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A,. 2008. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 14: 295-314.
41. Riegert C, Wedekind F, Hamida SB, et al,. 2008. Effects of ethanol and 3,4-methylenedioxymethamphetamine (MDMA) alone or in combination on spontaneous and evoked overflow of dopamine, serotonin and acetylcholine in striatal slices of the rat brain. Int J Neuropsychopharmacol 11: 743-63.
42. Robledo P, Trigo JM, Panayi F, de la Torre R, Maldonado R,. 2007. Behavioural and neurochemical effects of combined MDMA and THC administration in mice. Psychopharmacology 195: 255-264.
43. Rosa-Neto P, Gjedde A, Olsen AK, et al,. 2004. MDMA-evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain. Synapse 53: 222-33.
44. Sala M, Braida D,. 2005. Endocannabinoids and 3,4- methylenedioxymethamphetamine (MDMA) interaction. Pharmacol Biochem Behav 81: 407-16.
45. Schechter MD,. 1998. 'Candyflipping': synergistic discriminative effect of LSD and MDMA. Eur J Pharmacol 341: 131-4.
46. Schenk S, Hely L, Gittings D, Lake B, Daniela E,. 2008. Effects of priming injections of MDMA and cocaine on reinstatement of MDMA- and cocaine-seeking in rats. Drug Alcohol Depend 96: 249-55.
47. Schifano F, Oyefeso A, Corkery J, et al,. 2003. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002. Hum Psychopharmacol 18: 519-24.
48. Schlaepfer TE, Pearlson GD, Wong DF, Marenco S, Dannals RF,. 1997. PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects. Am J Psychiatry 154: 1209-13.
49. Scholey AB, Owen L, Gates J, et al,. 2011. Hair MDMA samples are consistent with reported Ecstasy use: findings from a study investigating effects of Ecstasy on mood and memory. Neuropsychobiology 63: 15-21.
50. Skinner HA, Sheu WJ,. 1982. Reliability of alcohol use indices. The lifetime drinking history and the MAST. J Stud Alcohol 43: 1157-70.
51. Sundhedsstyrelsen FP,. 2009. Narkotikasituationen i Danmark 2009. Aarsrapport til det europaeiske overvaagningscenter for narkotika og narkotikamisbrug, EMCDDA [The drug situation in Denmark 2009. Annual report to the European Monitoring Centre for Drugs and Drug Addiction EMCDDA]. Sundhedsstyrelsen, Koebenhavn.
52. Sundhedsstyrelsen FP,. 2010. Narkotikasituationen i Danmark 2010. Aarsrapport til det europaeiske overvaagningscenter for narkotika og narkotikamisbrug, EMCDDA [The drug situation in Denmark 2010. Annual report to the European Monitoring Centre for Drugs and Drug Addiction EMCDDA]. Sundhedsstyrelsen, Koebenhavn.
53. Thomasius R, Petersen K, Buchert R, et al,. 2003. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl) 167: 85-96.
54. Topp L, Hando J, Dillon P, Roche A, Solowij N,. 1999. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55: 105-15.
55. Tossmann P, Boldt S, Tensil MD,. 2001. The use of drugs within the techno party scene in European metropolitan cities. Eur Addict Res 7: 2-23.
56. Winstock AR, Griffiths P, Stewart D,. 2001. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 64: 9-17.
57. Wu LT, Schlenger WE, Galvin DM,. 2006. Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths. Drug Alcohol Depend 84: 102-13.
58. Wu LT, Parrott AC, Ringwalt CL, Yang C, Blazer DG,. 2009. The variety of ecstasy/MDMA users: results from the National Epidemiologic Survey on alcohol and related conditions. Am J Addict 18: 452-61.